NIKKEI 225
37,552.16 +113.55 (+0.30%) HANG SENG
16,828.93 +317.24 (+1.92%) CRUDE OIL
83.37 +1.47 (+1.79%) GOLD FUTURES
2,338.00 -8.40 (-0.36%) DOW
38,506.71 +266.73 (+0.70%) Bitcoin GBP
53,436.39 +200.04 (+0.38%)
Oxford BioDynamics PLC (LMQ.F)
| Previous close | 0.0625 |
| Open | 0.0620 |
| Bid | 0.0610 x N/A |
| Ask | 0.1500 x N/A |
| Day's range | 0.0620 - 0.0620 |
| 52-week range | 0.0450 - 0.5300 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Is Oxford BioDynamics (LON:OBD) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Business WireBupa UK to cover EpiSwitch® CiRT for customers with cancer
OXFORD, England, October 18, 2023--Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform and Bupa, the UK’s leading health insurer, announce a strategic agreement to give Bupa patients access to OBD’s EpiSwitch CiRT (Checkpoint inhibitor Response Test).
Business WireOxford BioDynamics Receives Reimbursement Code for EpiSwitch® Prostate Screening (PSE) Test
OXFORD, England, October 03, 2023--Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch 3D genomics platform, confirms the assignment and publication of a Proprietary Laboratory Analysis Code (PLA Code) by the American Medical Association’s CPT (Current Procedural Terminology) Editorial Board (https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes).
